このエントリーをはてなブックマークに追加
ID 52324
Sort Key
10
Title Alternative
Molecular targeted therapies in leukemia
FullText URL
Thumnail 126_49.pdf 455 KB
Author
Keywords
白血病
分子標的薬
チロシンキナーゼ阻害薬
Note
特集 (Feature Article)
Publication Title
岡山医学会雑誌
Published Date
2014-04-01
Volume
volume126
Issue
issue1
Publisher
岡山医学会
Publisher Alternative
Okayama Medical Association
Start Page
49
End Page
54
ISSN
0030-1558
NCID
AN00032489
Content Type
Journal Article
Related Url
http://www.okayama-u.ac.jp/user/oma/
OAI-PMH Set
岡山大学
language
日本語
Copyright Holders
Copyright (c) 2014 岡山医学会
File Version
publisher
Refereed
True
DOI
Eprints Journal Name
joma
References
1) Kantarjian HM, Talpaz M, O'Brien S, Jones D, Giles F, Garcia-Manero G, Faderl S, Ravandi F, Rios MB, Shan J, Cortes J : Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood (2006) 108, 1835-1840.
2) Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS, Wang J, Ipiña JJ, Kim DW, Ogura M, Pavlovsky C, Junghanss C, et al. : Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia : 2-year follow-up from a randomized phase 3 trial (DASISION). Blood (2012) 119, 1123-1129.
3) Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M : Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med (2001) 344, 1038-1042.
4) Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F, Kobayashi T, Ueda Y, Takeuchi M, Miyawaki S, Maruta A, Emi N, et al. : High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia : a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol (2006) 24, 460-466.
5) Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, et al. : A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med (2013) 369, 1783-1796.
6) Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, et al. : A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med (2012) 366, 799-807.
7) Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, et al. : JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med (2012) 366, 787-798.
8) Byrd JC, Furman RR, Coutre SE, Flinn ZW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, Jones JA, Zhao W, et al. : Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med (2013) 369, 32-42.
9) O'Brien S, Furman RR, Coutre SE, Sharman JP, Burger JA, Blum KA, Grant B, Richards DA, Coleman M, Wierda WG, Jones JA, Zhao W, et al. : Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma : an open-label, multicentre, phase 1b/2 trial. Lancet Oncol (2014) 15, 48-58.
10) Dietrich S, Glimm H, Andrulis M, von Kalle C, Ho AD, Zenz T : BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med (2012) 366, 2038-2040.
11) Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, Ellerton J, Larson RA, et al. : Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome : a study of the cancer and leukemia group B. J Clin Oncol (2002) 20, 2429-2440.
12) Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, et al. : Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes : a randomised, open-label, phase III study. Lancet Oncol (2009) 10, 223-232.